Navigation Links
A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer

A recent study has shown that a chemotherapy regimen combining vinorelbine (Navelbine) and mitoxantrone (Novantrone)// with the corticosteroid prednisone is effective in the treatment of hormone-refractory prostate cancer . Specialists say this treatment should be offered to symptomatic patients earlier in their disease.

However researchers added that a larger phase 2 study of this treatment regimen is planned. From a group of 66 patients who had advanced prostate cancer, the investigators recruited 12 for whom previous hormone therapy had failed in at least 3 lines of treatment.

The investigators included patients who had undergone palliative radiotherapy at any point during their disease. The patient’s median age was 67 years, with a range of 60 to 81 years. The patient’s median Eastern Cooperative Oncology Group performance status was 1, with a range of 0 to 2. All the patients had bone metastases, some with multiple sites. One patient had lymph node metastasis, and 1 had visceral disease. Three patients had significant ischaemic heart disease.

Each treatment cycle consisted of 10 to 12 mg/m2 of mitoxantrone on day 1, followed by 20 mg/m2 of vinorelbine on days 1 through 8. This cycle was repeated every 3 weeks. The patients also received 12.5 mg daily of prednisone. A total of 95 cycles were given, with a median of 7 cycles per patient and a range of 5 to 9 cycles per patient. Two patients repeated the treatment at 6 months and 12 months after the initial treatment. Among these patients, 50% had a marked decrease in pain and improvement in ECOG performance status, according to specialists. In 8 cycles, due to the response to treatment, the dose of vinorelbine was reduced 50% and in 4 cycles it was reduced 75%. The mitoxantrone dose was reduced 50% in 5 cycles. Although 1 patient had a drop in prostate specific antigen (PSA) of more than 50%, the computed tomography findings did not show an equivalent response.

The patients' median time to progression was 10 months, with a range of 6 months to over 20 months. Two patients are living; 8 died due to disease progression; and 2 died of other causes. The toxicity episodes consisted of 6 neutropaenic events, all afebrile. Otherwise, the investigators documented no Grade 4 haematological toxicity and no non-haematological toxicity.
'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Drug Combinations May Boost Stroke Risk
3. Combination therapy to treat breast cancer
4. Combination regime may work against prostate cancer
5. Smoking and Breast Cancer - A Deadly Combination
6. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
7. Combination Therapy Effective In Improving Lung Cancer Survival
8. Combination Therapy Found To Improves Stroke Recovery
9. Combination Therapy Found To Be More Effective In Treating Brain Cancer
10. Combination of Clopidogrel-aspirin is better for preventing stroke than only aspirin
11. New Combination Therapy Option for HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology: